Fairvalue-Calculator Fairvalue-Calculator
EN DE

Adaptive Biotechnologies Corporation (ADPT) Fair Value & Analysis

Healthcare · US · Market cap $2.6B

Price$17.23
Fair Value$6.15
Upside-64.3%
Quality93/100
Evidence: Low Range $4.61 – $7.69

Fair value as of: Jun 24, 2026

Analysis

Adaptive Biotechnologies Corporation (ADPT) currently trades at $17.23, while our model-based Fair Value estimate is $6.15 — implying the stock looks roughly 64.3% overvalued today. We read business quality at 93/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Open the full interactive analysis →

Similar stocks

Thermo Fisher Scientific Inc (TMO) -58% Danaher Corporation (DHR) -37% WuXi AppTec Co (WUXAY) +35% IDEXX Laboratories, Inc (IDXX) -54% Lonza Group (LZAGY) -59% Agilent Technologies, Inc (A) -50%

Frequently asked questions

Is Adaptive Biotechnologies Corporation (ADPT) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $6.15 versus a price of $17.23 — about −64% (overvalued). Model-based estimate, not financial advice.
What is the fair value of ADPT?
Our 21-model fair value for Adaptive Biotechnologies Corporation is $6.15 (as of Jun 24, 2026), built from audited fundamentals. The current price is $17.23.
What is the quality score of ADPT?
Adaptive Biotechnologies Corporation has a Quality Score of 93/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.